Format

Send to

Choose Destination
Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):239-246. doi: 10.1016/j.bbcan.2018.06.004. Epub 2018 Jun 28.

Preclinical models for precision oncology.

Author information

1
Department of Oncology, Biomedical Research Institute - INCLIVA, University of Valencia, Valencia, Spain; Candiolo Cancer Institute-FPO, IRCCS, Candiolo, TO, Italy; centro de investigación biomedical en red CIBERONC, Spain. Electronic address: mibarrolavillava@incliva.es.
2
Department of Oncology, Biomedical Research Institute - INCLIVA, University of Valencia, Valencia, Spain; centro de investigación biomedical en red CIBERONC, Spain.
3
Candiolo Cancer Institute-FPO, IRCCS, Candiolo, TO, Italy; Department of Oncology, University of Torino, SP 142 km 3.95, Candiolo, TO, Italy. Electronic address: alberto.bardelli@unito.it.

Abstract

Precision medicine approaches have revolutionized oncology. Personalized treatments require not only identification of the driving molecular alterations, but also development of targeted therapies and diagnostic tests to identify the appropriate patient populations for clinical trials and subsequent therapeutic implementation. Preclinical in vitro and in vivo models are widely used to predict efficacy of newly developed treatments. Here we discuss whether, and to what extent, preclinical models including cell lines, organoids and tumorgrafts recapitulate key features of human tumors. The potential of preclinical models to anticipate treatment efficacy and clinical benefit is also presented, using examples in different tumor types.

KEYWORDS:

Organoids; Patient-derived xenografts (PDX); Preclinical models

PMID:
29959990
DOI:
10.1016/j.bbcan.2018.06.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center